News tagged with capecitabine
Capecitabine
Capecitabine (INN) ( /keɪpˈsaɪtəbiːn/) (Xeloda, Roche) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.[citation needed] The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil.[citation needed]
For more information about Capecitabine, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Sorafenib significantly improves the length of time before breast cancer worsens
Berlin, Germany: One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy ...
Sep 23, 2009 |
not rated yet |
0
Triple drug combination is promising option to treat metastatic HER2+ breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options.
May 15, 2009 |
5 / 5 (1) |
0